Potential of resveratrol in the treatment of systemic lupus erythematosus (Review)
- Authors:
- Rongxiu Huo
- Yanting Yang
- Xiaocong Huo
- Danli Meng
- Rongjun Huang
- Yang Yang
- Jinying Lin
- Yijia Huang
- Xia Zhu
- Chengcheng Wei
- Xinxiang Huang
-
Affiliations: Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530016, P.R. China - Published online on: August 14, 2024 https://doi.org/10.3892/mmr.2024.13306
- Article Number: 182
-
Copyright: © Huo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Gergianaki I, Fanouriakis A, Repa A, Tzanakakis M, Adamichou C, Pompieri A, Spirou G, Bertsias A, Kabouraki E, Tzanakis I, et al: Epidemiology and burden of systemic lupus erythematosus in a Southern European population: Data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis. 76:1992–2000. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fanouriakis A, Tziolos N, Bertsias G and Boumpas DT: Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 80:14–25. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Fang Q, Li T, Chen P, Wu Y, Wang T, Mo L, Ou J and Nandakumar KS: Comparative Analysis on Abnormal methylome of differentially expressed genes and disease pathways in the immune cells of RA and SLE. Front Immunol. 12:6680072021. View Article : Google Scholar : PubMed/NCBI | |
|
Bentham J, Morris DL, Graham DSC, Pinder CL, Tombleson P, Behrens TW, Martín J, Fairfax BP, Knight JC, Chen L, et al: Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet. 47:1457–1464. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fava A and Petri M: Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 96:1–13. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, et al: 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 78:736–745. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Mitjavila F, Castro Salomó A, Cuquet Pedragosa J, Ortiz-Santamaria V, Mauri Plana M and Cortés-Hernández J: Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: A randomised clinical trial. Ann Rheum Dis. 76:1575–1582. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, et al: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 377:721–731. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O'Malley CD, Saag K and Curtis JR: Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int. 27:3239–3249. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Singh BK and Singh S: Systemic lupus erythematosus and infections. Reumatismo. 72:154–169. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shi H, Gudjonsson JE and Kahlenberg JM: Treatment of cutaneous lupus erythematosus: Current approaches and future strategies. Curr Opin Rheumatol. 32:208–214. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cardile V, Chillemi R, Lombardo L, Sciuto S, Spatafora C and Tringali C: Antiproliferative activity of methylated analogues of E- and Z-resveratrol. Z Naturforsch C J Biosci. 62:189–195. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Weiskirchen S and Weiskirchen R: Resveratrol: How much wine do you have to drink to stay healthy? Adv Nutr. 7:706–718. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Raj P, Thandapilly SJ, Wigle J, Zieroth S and Netticadan T: A comprehensive analysis of the efficacy of resveratrol in atherosclerotic cardiovascular disease, myocardial infarction and heart failure. Molecules. 26:66002021. View Article : Google Scholar : PubMed/NCBI | |
|
Švajger U and Jeras M: Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases. Int Rev Immunol. 31:202–222. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Paik JH, Cho D, Cho JA and Kim CW: Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells. Int Immunopharmacol. 8:542–547. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Malaguarnera L: Influence of resveratrol on the immune response. Nutrients. 11:9462019. View Article : Google Scholar : PubMed/NCBI | |
|
Jhou JP, Chen SJ, Huang HY, Lin WW, Huang DY and Tzeng SJ: Upregulation of FcγRIIB by resveratrol via NF-κB activation reduces B-cell numbers and ameliorates lupus. Exp Mol Med. 49:e3812017. View Article : Google Scholar : PubMed/NCBI | |
|
Oliveira ALB, Monteiro VVS, Navegantes-Lima KC, Reis JF, Gomes RS, Rodrigues DVS, Gaspar SLF and Monteiro MC: Resveratrol role in autoimmune disease-a mini-review. Nutrients. 9:13062017. View Article : Google Scholar : PubMed/NCBI | |
|
Fu Y, Yan M, Xie C, Hu J, Zeng X and Hu Q: Polydatin relieves paraquat-induced human MRC-5 fibroblast injury through inhibiting the activation of the NLRP3 inflammasome. Ann Transl Med. 8:7652020. View Article : Google Scholar : PubMed/NCBI | |
|
Yahfoufi N, Alsadi N, Jambi M and Matar C: The immunomodulatory and anti-inflammatory role of polyphenols. Nutrients. 10:16182018. View Article : Google Scholar : PubMed/NCBI | |
|
Han GM, Chen SL, Shen N, Ye S, Bao CD and Gu YY: Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun. 4:177–186. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ishii T, Onda H, Tanigawa A, Ohshima S, Fujiwara H, Mima T, Katada Y, Deguchi H, Suemura M, Miyake T, et al: Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients. DNA Res. 12:429–439. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Pan L, Lu MP, Wang JH, Xu M and Yang SR: Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 16:19–30. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Smith CK and Kaplan MJ: The role of neutrophils in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol. 27:448–453. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Berthelot JM, Le Goff B, Neel A, Maugars Y and Hamidou M: NETosis: At the crossroads of rheumatoid arthritis, lupus, and vasculitis. Joint Bone Spine. 84:255–262. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fresneda Alarcon M, McLaren Z and Wright HL: Neutrophils in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus: Same Foe Different M.O. Front immunol. 12:6496932021. View Article : Google Scholar : PubMed/NCBI | |
|
Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM, Shin MH, Park JJ, Kim TJ, Lee SS, et al: Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum. 60:1753–1763. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Riccieri V, Spadaro A, Parisi G, Taccari E, Moretti T, Bernardini G, Favaroni M and Strom R: Down-regulation of natural killer cells and of gamma/delta T cells in systemic lupus erythematosus. Does it correlate to autoimmunity and to laboratory indices of disease activity? Lupus. 9:333–337. 2000.PubMed/NCBI | |
|
Huang Z, Fu B, Zheng SG, Li X, Sun R, Tian Z and Wei H: Involvement of CD226+ NK cells in immunopathogenesis of systemic lupus erythematosus. J Immunol. 186:3421–3431. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Eloranta ML, Lövgren T, Finke D, Mathsson L, Rönnelid J, Kastner B, Alm GV and Rönnblom L: Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 60:2418–2427. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P, Musset L, Debré P, Amoura Z and Vieillard V: Phenotype and function of natural killer cells in systemic lupus erythematosus: Excess interferon-γ production in patients with active disease. Arthritis Rheum. 63:1698–1706. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hodge DL, Berthet C, Coppola V, Kastenmüller W, Buschman MD, Schaughency PM, Shirota H, Scarzello AJ, Subleski JJ, Anver MR, et al: IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice. J Autoimmun. 53:33–45. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu M, Liu J, Hao S, Wu P, Zhang X, Xiao Y, Jiang G and Huang X: Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: Relation to disease activity. Clin Rheumatol. 37:2675–2684. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nandakumar KS and Nündel K: Editorial: Systemic lupus erythematosus-predisposition factors, pathogenesis, diagnosis, treatment and disease models. Front Immunol. 13:11181802022. View Article : Google Scholar : PubMed/NCBI | |
|
Horwitz DA, Gray JD, Behrendsen SC, Kubin M, Rengaraju M, Ohtsuka K and Trinchieri G: Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum. 41:838–844. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HY, Hong YK, Yun HJ, Kim YM, Kim JR and Yoo WH: Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus. Rheumatology (Oxford). 47:789–794. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ma J, Yu J, Tao X, Cai L, Wang J and Zheng SG: The imbalance between regulatory and IL-17-secreting CD4+ T cells in lupus patients. Clin Rheumatol. 29:1251–1258. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu Y, Zhou X, Liu Y, Tan S and Li Y: The role of sirtuin-1 in immune response and systemic lupus erythematosus. Front Immunol. 12:6323832021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Zhang XL, Zhang GH and Gao YF: Artesunate promotes Th1 differentiation from CD4+ T cells to enhance cell apoptosis in ovarian cancer via miR-142. Braz J Med Biol Res. 52:e79922019. View Article : Google Scholar : PubMed/NCBI | |
|
Dorgham K, Amoura Z, Parizot C, Arnaud L, Frances C, Pionneau C, Devilliers H, Pinto S, Zoorob R, Miyara M, et al: Ultraviolet light converts propranolol, a nonselective β-blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand. Eur J Immunol. 45:3174–3187. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Guo NH, Fu X, Zi FM, Song Y, Wang S and Cheng J: The potential therapeutic benefit of resveratrol on Th17/Treg imbalance in immune thrombocytopenic purpura. Int Immunopharmacol. 73:181–192. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Delmas D, Limagne E, Ghiringhelli F and Aires V: Immune Th17 lymphocytes play a critical role in the multiple beneficial properties of resveratrol. Food Chem Toxicol. 137:1110912020. View Article : Google Scholar : PubMed/NCBI | |
|
Fillatreau S, Sweenie CH, McGeachy MJ, Gray D and Anderton SM: B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 3:944–950. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Choi JY, Ho JHE, Pasoto SG, Bunin V, Kim ST, Carrasco S, Borba EF, Gonçalves CR, Costa PR, Kallas EG, et al: Circulating follicular helper-like T cells in systemic lupus erythematosus: Association with disease activity. Arthritis Rheumatol. 67:988–999. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, Sun X, Vandenberg K, Rockman S, Ding Y, et al: Circulating precursor CCR7(lo)PD-1(hi) CXCR5+ CD4+ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity. 39:770–781. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, Sweet MJ, Smyth MJ, Mackay CR and Mackay F: BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med. 204:1959–1971. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sequeira J, Boily G, Bazinet S, Saliba S, He X, Jardine K, Kennedy C, Staines W, Rousseaux C, Mueller R and McBurney MW: sirt1-null mice develop an autoimmune-like condition. Exp Cell Res. 314:3069–3074. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Q, Yan C, Xin M, Han L, Zhang Y and Sun M: Sirtuin 1 (Sirt1) overexpression in BaF3 cells contributes to cell proliferation promotion, apoptosis resistance and pro-inflammatory cytokine production. Med Sci Monit. 23:1477–1482. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Delmas D and Lin HY: Role of membrane dynamics processes and exogenous molecules in cellular resveratrol uptake: Consequences in bioavailability and activities. Mol Nutr Food Res. 55:1142–1153. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ho Y, Li ZL, Shih YJ, Chen YR, Wang K, Whang-Peng J, Lin HY and Davis PJ: Integrin αvβ3 in the mediating effects of dihydrotestosterone and resveratrol on breast cancer cell proliferation. Int J Mol Sci. 21:29062020. View Article : Google Scholar : PubMed/NCBI | |
|
Bonizzi G and Karin M: The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25:280–288. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Schwager J, Richard N, Widmer F and Raederstorff D: Resveratrol distinctively modulates the inflammatory profiles of immune and endothelial cells. BMC Complement Altern Med. 17:3092017. View Article : Google Scholar : PubMed/NCBI | |
|
Svajger U, Obermajer N and Jeras M: Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation. Immunology. 129:525–535. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sener G, Tuğtepe H, Yüksel M, Cetinel S, Gedik N and Yeğen BC: Resveratrol improves ischemia/reperfusion-induced oxidative renal injury in rats. Arch Med Res. 37:822–829. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W, Sun L, Zhang P, Song J and Liu W: An anti-inflammatory cell-free collagen/resveratrol scaffold for repairing osteochondral defects in rabbits. Acta Biomater. 10:4983–4995. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Orsu P, Murthy BVSN and Akula A: Cerebroprotective potential of resveratrol through anti-oxidant and anti-inflammatory mechanisms in rats. J Neural Transm (Vienna). 120:1217–1223. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bo S, Ciccone G, Castiglione A, Gambino R, De Michieli F, Villois P, Durazzo M, Cavallo-Perin P and Cassader M: Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem. 20:1323–1331. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Balkrishna A, Sinha S, Kumar A, Arya V, Gautam AK, Valis M, Kuca K, Kumar D and Amarowicz R: Sepsis-mediated renal dysfunction: Pathophysiology, biomarkers and role of phytoconstituents in its management. Biomed Pharmacother. 165:1151832023. View Article : Google Scholar : PubMed/NCBI | |
|
Liu FC, Tsai HI and Yu HP: Organ-protective effects of red wine extract, resveratrol, in oxidative stress-mediated reperfusion injury. Oxid Med Cell Longev. 2015:5686342015. View Article : Google Scholar : PubMed/NCBI | |
|
de Souza Andrade MM, Leal VNC, Fernandes IG, Gozzi-Silva SC, Beserra DR, Oliveira EA, Teixeira FME, Yendo TM, Sousa MDGT, Teodoro WR, et al: Resveratrol downmodulates neutrophil extracellular trap (NET) generation by neutrophils in patients with severe COVID-19. Antioxidants (Basel). 11:16902022. View Article : Google Scholar : PubMed/NCBI | |
|
Rieder SA, Nagarkatti P and Nagarkatti M: Multiple anti-inflammatory pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin B-induced lung injury. Br J Pharmacol. 167:1244–1258. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Li Q, Huyan T, Ye LJ, Li J, Shi JL and Huang QS: Concentration-dependent biphasic effects of resveratrol on human natural killer cells in vitro. J Agric Food Chem. 62:10928–10935. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang ZL, Luo XF, Li MT, Xu D, Zhou S, Chen HZ, Gao N, Chen Z, Zhang LL and Zeng XF: Resveratrol possesses protective effects in a pristane-induced lupus mouse model. PLoS One. 9:e1147922014. View Article : Google Scholar : PubMed/NCBI | |
|
Yao Y, Zhu J, Qin S, Zhou Z, Zeng Q, Long R, Mao Z, Dong X, Zhao R, Zhang R, et al: Resveratrol induces autophagy impeding BAFF-stimulated B-cell proliferation and survival by inhibiting the Akt/mTOR pathway. Biochem Pharmacol. 202:1151392022. View Article : Google Scholar : PubMed/NCBI | |
|
Wållberg M and Cooke A: Immune mechanisms in type 1 diabetes. Trends Immunol. 34:583–591. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Battaglia M: Neutrophils and type 1 autoimmune diabetes. Curr Opin Hematol. 21:8–15. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kaur G, Padiya R, Adela R, Putcha UK, Reddy GS, Reddy BR, Kumar KP, Chakravarty S and Banerjee SK: Garlic and resveratrol attenuate diabetic complications, loss of β-cells, pancreatic and hepatic oxidative stress in streptozotocin-induced diabetic rats. Front Pharmacol. 7:3602016. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SM, Yang H, Tartar DM, Gao B, Luo X, Ye SQ, Zaghouani H and Fang D: Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. Diabetologia. 54:1136–1146. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yonamine CY, Pinheiro-Machado E, Michalani ML, Freitas HS, Okamoto MM, Corrêa-Giannella ML and Machado UF: Resveratrol improves glycemic control in insulin-treated diabetic rats: Participation of the hepatic territory. Nutr Metab (Lond). 13:442016. View Article : Google Scholar : PubMed/NCBI | |
|
Boirivant M and Cossu A: Inflammatory bowel disease. Oral Dis. 18:1–15. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Singh UP, Singh NP, Busbee B, Guan H, Singh B, Price RL, Taub DD, Mishra MK, Nagarkatti M and Nagarkatti PS: Alternative medicines as emerging therapies for inflammatory bowel diseases. Int Rev Immunol. 31:66–84. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tian T, Wang Z and Zhang J: Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies. Oxid Med Cell Longev. 2017:45351942017. View Article : Google Scholar : PubMed/NCBI | |
|
Sánchez-Fidalgo S, Cárdeno A, Villegas I, Talero E and de la Lastra CA: Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol. 633:78–84. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Samsami-Kor M, Daryani NE, Asl PR and Hekmatdoost A: Anti-inflammatory effects of resveratrol in patients with ulcerative colitis: A randomized, double-blind, placebo-controlled pilot study. Arch Med Res. 46:280–285. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hänsel A, Günther C, Ingwersen J, Starke J, Schmitz M, Bachmann M, Meurer M, Rieber EP and Schäkel K: Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J Allergy Clin Immunol. 127:787–794.e1-e9. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lowes MA, Suárez-Fariñas M and Krueger JG: Immunology of psoriasis. Annu Rev Immunol. 32:227–255. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lynde CW, Poulin Y, Vender R, Bourcier M and Khalil S: Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 71:141–150. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kjær TN, Thorsen K, Jessen N, Stenderup K and Pedersen SB: Resveratrol ameliorates imiquimod-induced psoriasis-like skin inflammation in mice. PLoS One. 10:e01265992015. View Article : Google Scholar : PubMed/NCBI | |
|
Navegantes KC, de Souza Gomes R, Pereira PAT, Czaikoski PG, Azevedo CHM and Monteiro MC: Immune modulation of some autoimmune diseases: The critical role of macrophages and neutrophils in the innate and adaptive immunity. J Transl Med. 15:362017. View Article : Google Scholar : PubMed/NCBI | |
|
Tanaka T, Hishitani Y and Ogata A: Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics. 8:141–153. 2014.PubMed/NCBI | |
|
Brzustewicz E and Bryl E: The role of cytokines in the pathogenesis of rheumatoid arthritis-Practical and potential application of cytokines as biomarkers and targets of personalized therapy. Cytokine. 76:527–536. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Engler A, Tange C, Frank-Bertoncelj M, Gay RE, Gay S and Ospelt C: Regulation and function of SIRT1 in rheumatoid arthritis synovial fibroblasts. J Mol Med (Berl). 94:173–182. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ma C, Wang Y, Dong L, Li M and Cai W: Anti-inflammatory effect of resveratrol through the suppression of NF-κB and JAK/STAT signaling pathways. Acta Biochim Biophys Sin (Shanghai). 47:207–213. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SJ, Thien Quach CH, Jung KH, Paik JY, Lee JH, Park JW and Lee KH: Oxidized low-density lipoprotein stimulates macrophage 18F-FDG uptake via hypoxia-inducible factor-1α activation through Nox2-dependent reactive oxygen species generation. J Nucl Med. 55:1699–1705. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai MH, Hsu LF, Lee CW, Chiang YC, Lee MH, How JM, Wu CM, Huang CL and Lee IT: Resveratrol inhibits urban particulate matter-induced COX-2/PGE2 release in human fibroblast-like synoviocytes via the inhibition of activation of NADPH oxidase/ROS/NF-κB. Int J Biochem Cell Biol. 88:113–123. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xuzhu G, Komai-Koma M, Leung BP, Howe HS, McSharry C, McInnes IB and Xu D: Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann Rheum Dis. 71:129–135. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wahba MGF, Messiha BAS and Abo-Saif AA: Protective effects of fenofibrate and resveratrol in an aggressive model of rheumatoid arthritis in rats. Pharm Biol. 54:1705–1715. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Avendaño-Vázquez SE, Dhir A, Bembich S, Buratti E, Proudfoot N and Baralle FE: Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev. 26:1679–1684. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Malaspina A, Puentes F and Amor S: Disease origin and progression in amyotrophic lateral sclerosis: An immunology perspective. Int Immunol. 27:117–129. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Higashida K, Kim SH, Jung SR, Asaka M, Holloszy JO and Han DH: Effects of resveratrol and SIRT1 on PGC-1α activity and mitochondrial biogenesis: A reevaluation. PLoS Biol. 11:e10016032013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao W, Varghese M, Yemul S, Pan Y, Cheng A, Marano P, Hassan S, Vempati P, Chen F, Qian X and Pasinetti GM: Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1α) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis. Mol Neurodegener. 6:512011. View Article : Google Scholar : PubMed/NCBI | |
|
McFarlane IG: Pathogenesis of autoimmune hepatitis. Biomed Pharmacother. 53:255–263. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Ichiki Y, Aoki CA, Bowlus CL, Shimoda S, Ishibashi H and Gershwin ME: T cell immunity in autoimmune hepatitis. Autoimmun Rev. 4:315–321. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gianchecchi E and Fierabracci A: Insights on the effects of resveratrol and some of its derivatives in cancer and autoimmunity: A molecule with a dual activity. Antioxidants (Basel). 9:912020. View Article : Google Scholar : PubMed/NCBI | |
|
Huang TH, Chen CC, Liu HM, Lee TY and Shieh SH: Resveratrol pretreatment attenuates concanavalin a-induced hepatitis through reverse of aberration in the immune response and regenerative capacity in aged mice. Sci Rep. 7:27052017. View Article : Google Scholar : PubMed/NCBI | |
|
Biswas S, Bieber K and Manz RA: IL-10 revisited in systemic lupus erythematosus. Front Immunol. 13:9709062022. View Article : Google Scholar : PubMed/NCBI | |
|
Facciotti F, Larghi P, Bosotti R, Vasco C, Gagliani N, Cordiglieri C, Mazzara S, Ranzani V, Rottoli E, Curti S, et al: Evidence for a pathogenic role of extrafollicular, IL-10-producing CCR6+B helper T cells in systemic lupus erythematosus. Proc Natl Acad Sci USA. 117:7305–7316. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Caielli S, Veiga DT, Balasubramanian P, Athale S, Domic B, Murat E, Banchereau R, Xu Z, Chandra M, Chung CH, et al: A CD4+ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate. Nat Med. 25:75–81. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Klonowska-Szymczyk A, Kulczycka-Siennicka L, Robak T, Smolewski P, Cebula-Obrzut B and Robak E: The impact of agonists and antagonists of TLR3 and TLR9 on concentrations of IL-6, IL10 and sIL-2R in culture supernatants of peripheral blood mononuclear cells derived from patients with systemic lupus erythematosus. Postepy Hig Med Dosw (Online). 71:867–875. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Voloshyna I, Teboul I, Littlefield MJ, Siegart NM, Turi GK, Fazzari MJ, Carsons SE, DeLeon J and Reiss AB: Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux. Exp Biol Med (Maywood). 241:1611–1619. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Satoh M and Reeves WH: Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med. 180:2341–2346. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Tian J, Huang T, Chen J, Wang J, Chang S, Xu H, Zhou X, Yang J, Xue Y, Zhang T, et al: SIRT1 slows the progression of lupus nephritis by regulating the NLRP3 inflammasome through ROS/TRPM2/Ca2+ channel. Clin Exp Med. 23:3465–3478. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Pannu N and Bhatnagar A: Combinatorial therapeutic effect of resveratrol and piperine on murine model of systemic lupus erythematosus. Inflammopharmacology. 28:401–424. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Pannu N and Bhatnagar A: Prophylactic effect of resveratrol and piperine on pristane-induced murine model of lupus-like disease. Inflammopharmacology. 28:719–735. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Feng X, Li H, Rumbin AA, Wang X, La Cava A, Brechtelsbauer K, Castellani LW, Witztum JL, Lusis AJ and Tsao BP: ApoE-/-Fas-/-C57BL/6 mice: A novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. J Lipid Res. 48:794–805. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kasselman LJ, Renna HA, Voloshyna I, Pinkhasov A, Gomolin IH, Teboul I, De Leon J, Carsons SE and Reiss AB: Cognitive changes mediated by adenosine receptor blockade in a resveratrol-treated atherosclerosis-prone lupus mouse model. J Tradit Complement Med. 12:447–454. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Wang Z, Lei H and Zhang D: Recent progress in nanotechnology-based drug carriers for resveratrol delivery. Drug Deliv. 30:21742062023. View Article : Google Scholar : PubMed/NCBI | |
|
Walle T, Hsieh F, DeLegge MH, Oatis JE Jr and Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 32:1377–1382. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sergides C, Chirilă M, Silvestro L, Pitta D and Pittas A: Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. Exp Ther Med. 11:164–170. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Summerlin N, Soo E, Thakur S, Qu Z, Jambhrunkar S and Popat A: Resveratrol nanoformulations: Challenges and opportunities. Int J Pharm. 479:282–290. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zupančič Š, Lavrič Z and Kristl J: Stability and solubility of trans-resveratrol are strongly influenced by pH and temperature. Eur J Pharm Biopharm. 93:196–204. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Novelle MG, Wahl D, Diéguez C, Bernier M and de Cabo R: Resveratrol supplementation: Where are we now and where should we go? Ageing Res Rev. 21:1–15. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shaito A, Posadino AM, Younes N, Hasan H, Halabi S, Alhababi D, Al-Mohannadi A, Abdel-Rahman WM, Eid AH, Nasrallah GK and Pintus G: Potential adverse effects of resveratrol: A literature review. Int J Mol Sci. 21:20842020. View Article : Google Scholar : PubMed/NCBI | |
|
Hebbar V, Shen G, Hu R, Kim BR, Chen C, Korytko PJ, Crowell JA, Levine BS and Kong AN: Toxicogenomics of resveratrol in rat liver. Life Sci. 76:2299–2314. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Crowell JA, Korytko PJ, Morrissey RL, Booth TD and Levine BS: Resveratrol-associated renal toxicity. Toxicol Sci. 82:614–619. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Zhao M, Zhou Y, Wang C, Yuan Y, Li L, Bresette W, Chen Y, Cheng J, Lu Y and Liu J: Resveratrol exerts dose-dependent anti-fibrotic or pro-fibrotic effects in kidneys: A potential risk to individuals with impaired kidney function. Phytomedicine. 57:223–235. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Moon RT, Kohn AD, De Ferrari GV and Kaykas A: WNT and beta-catenin signalling: Diseases and therapies. Nat Rev Genet. 5:691–701. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, Brown K, Steward WP and Gescher AJ: Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila). 4:1419–1425. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stødkilde-Jørgensen H, Møller N, Jessen N, Pedersen SB and Jørgensen JO: High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 62:1186–1195. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mankowski RT, You L, Buford TW, Leeuwenburgh C, Manini TM, Schneider S, Qiu P and Anton SD: Higher dose of resveratrol elevated cardiovascular disease risk biomarker levels in overweight older adults-A pilot study. Exp Gerontol. 131:1108212020. View Article : Google Scholar : PubMed/NCBI | |
|
Ramírez-Garza SL, Laveriano-Santos EP, Marhuenda-Muñoz M, Storniolo CE, Tresserra-Rimbau A, Vallverdú-Queralt A and Lamuela-Raventós RM: Health effects of resveratrol: Results from human intervention trials. Nutrients. 10:18922018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang T, He Q, Liu Y, Chen Z and Hu H: Efficacy and safety of resveratrol supplements on blood lipid and blood glucose control in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2021:56441712021.PubMed/NCBI | |
|
Goh KP, Lee HY, Lau DP, Supaat W, Chan YH and Koh AFY: Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int J Sport Nutr Exerc Metab. 24:2–13. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sattarinezhad A, Roozbeh J, Shirazi Yeganeh B, Omrani GR and Shams M: Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial. Diabetes Metab. 45:53–59. 2019. View Article : Google Scholar : PubMed/NCBI |
